EVOTF — Evotec SE

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1412558 · Germany
Last close
$3.33
Market Cap
$590.83M
52W High
$8.01
52W Low
$3.33
ADV30
0
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 164,926,000 19,795,000 -27,115,000 -26,744,000 1,504,970,000 299,012,000 863,309,000
Jun 2026 143,479,000 -1,579,000 -89,322,000 -46,649,000 1,573,975,000 348,356,000 908,397,000
Mar 2026 156,644,000 -1,569,000 -46,423,000 -121,936,000 1,639,812,000 387,912,000 940,192,000
Dec 2025 253,273,000 78,463,000 37,208,000 14,624,000 1,713,945,000 401,786,000 900,241,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-91,390,000
Investing CF
$237,187,000
Financing CF
$-23,201,000
CapEx
$-45,331,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.11
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-971,215,000
Inventory
$37,710,000
Receivables
$171,272,000
ST Investments
$119,466,000
EBIT TTM
$-149,641,000
Pretax Income TTM
$-162,860,000
Interest Exp TTM
$13,219,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$717,283,008
EBITDA
$-73,181,000
Free Cash Flow
$-80,990,624
Enterprise Value
$701,518,784
Total Cash
$465,587,008
Total Debt
$475,865,984
Shares Out
177,694,559
Trailing EPS
$-1.26
Book Value
$4.35
ROE
-26.1%
ROA
-5.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 788,373,000 -55,818,000 -103,517,000 1,713,945,000 900,241,000 813,704,000 -9,179,000
Dec 2024 796,967,000 -78,919,000 -196,078,000 1,912,502,000 959,977,000 952,525,000 18,220,000
Dec 2023 781,426,000 -26,628,000 -83,913,000 2,252,468,000 1,132,560,000 1,119,908,000 36,439,000
Dec 2022 751,448,000 20,850,000 -175,655,000 2,257,247,000 1,070,063,000 1,187,184,000 205,811,000

Peers — same industry

TickerNameMarket CapLastDaily %
IMMX Immix Biopharma, Inc. $603.45M $7.20 —
CLYM Climb Bio, Inc. $574.46M $9.78 —
ABUS Arbutus Biopharma Corp $620.84M $4.05 —
WVE Wave Life Sciences, Inc. $560.13M $2.84 —
ZVRA ZEVRA THERAPEUTICS, INC. $559.34M $9.40 —

News headlines (Yahoo Finance, 1h cache)

Evotec SE (EVOTF) (Q3 2026) Earnings Call Highlights: Near-Breakeven EBITDA, Horizon Savings ...
2026-11-06 01:16 · Yahoo
Here's Why Evotec (EVO) Looks Ripe for Bottom Fishing
2026-11-18 13:55 · Yahoo
Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape Testing
2026-11-16 15:45 · Yahoo
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
2026-11-16 06:57 · Yahoo
Evotec SE (EVO) Q3 2026 Earnings Call Transcript
2026-11-05 21:14 · Yahoo
What Evotec (EVO) Said on Its Q3 Earnings Call
2026-11-05 20:14 · Yahoo
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
2026-11-05 07:18 · Yahoo
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
2026-10-29 07:00 · Yahoo
Did Evotec’s 60% Drop Catch You Out? What Investors Missed
2026-10-25 16:06 · Yahoo
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
2026-10-15 06:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.